Clinical Trial Search

Primary: Muscular Activity of Erector Spinae Muscle. — 11.2; 11.1; 12.3; 10.4 %MVE

Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039

Primary: Proportion of Participants With a Pathologic Complete Response Rate — .26; .80 proportion of participants

Primary: Number of Participants With Adverse Events — 3 Participants

Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants

Primary: Number of Participants With Incidence of Major Bleeding — 1; 1 Participants

Primary: Change in Basal Insulin Rate — 1.8; 1.49 Units of insulin

Primary: Number of Participants With Vital Signs Data Meeting Pre-Specified Criteria (Single Ascending Dose [SAD] Period) — 2; 2; 1; 0 Participants

Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants

Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters

Primary: The Change From Baseline in ALS Functional Rating Scale-Revised (ALSFRS-R) Total Score to the Average of Values Obtained at the End of Weeks 8 and 12 of Double-blind…

Primary: Maximum Tolerated Dose (MTD) of Selinexor With Sorafenib — 60; 60 Milligrams

Primary: Frequency of Adverse Events in the CHMI-trans Model — 95; 95; 107; 52 Adverse events

Primary: Tear Osmolarity — 303; 303 mOsM/L

Primary: Frequency of HIV Testing by Internet-recruited MSM. — 777; 215 Participants